What is the recommended rituximab regimen, screening, and monitoring for treating proteinuria in minimal‑change disease?

Rituximab for Minimal Change Disease with Proteinuria

Recommended Rituximab Regimen

For adults with steroid-dependent or frequently relapsing minimal change disease (MCD), rituximab should be administered as either 375 mg/m² intravenously weekly for 4 weeks OR 1000 mg intravenously as two doses spaced 2 weeks apart. 1

Dosing Protocols

• Standard lymphoma-type protocol: 375 mg/m² IV weekly for 4 consecutive weeks 1
• Rheumatology-type protocol: 1000 mg IV on day 1 and day 15 (two weeks apart) 1
• Both protocols produce comparable B-cell depletion and similar clinical remission rates in adults 1

Alternative Low-Dose Regimens

• Some centers use 200 mg weekly × 4 doses followed by 200 mg every 6 months for maintenance, which has shown 95.45% remission rates with fewer side effects 2
• Extended infusion protocol of 375 mg/m² once every three weeks for 3 doses combined with corticosteroids achieved complete remission in 88% of patients with mean remission maintenance of 11.6 months 3

Pre-Treatment Screening Requirements

Mandatory Infectious Disease Screening

• Hepatitis B screening (HBsAg, anti-HBc, anti-HBs) is essential, as reactivation can be fatal 4
• Hepatitis C screening should be performed 4
• Screen for latent tuberculosis with tuberculin skin test or interferon-gamma release assay 4
• Consider screening for HIV in high-risk populations 4

Baseline Laboratory Assessment

• Complete blood count with differential 4
• Comprehensive metabolic panel including serum creatinine and eGFR 5
• Serum albumin level (important prognostic factor—low albumin predicts higher relapse risk) 6
• Quantitative immunoglobulins (IgG, IgA, IgM) to establish baseline 4
• 24-hour urine protein or urine protein-to-creatinine ratio 5

Cardiac Evaluation

• Perform cardiac monitoring during and after all infusions for patients with history of arrhythmia or angina 4
• Baseline ECG should be considered in patients with cardiovascular risk factors 4

Vaccination Status

• Administer all non-live vaccines at least 4 weeks prior to rituximab initiation 4
• Live vaccines are contraindicated before and during treatment 4
• Pneumococcal, influenza, and hepatitis B vaccines should be prioritized 4

Monitoring During Treatment

Infusion Monitoring

• Premedicate with acetaminophen and antihistamine (e.g., diphenhydramine) 30-60 minutes before each infusion to reduce infusion reactions 4
• Monitor vital signs every 30 minutes during infusion and for 1-2 hours post-infusion 4
• Have emergency resuscitation equipment immediately available for severe infusion reactions 4

Laboratory Monitoring Schedule

During active treatment (first 6 months):

• Complete blood count: every 2-4 weeks to monitor for cytopenias 4
• Serum creatinine and eGFR: every 2-4 weeks 5
• Urine protein-to-creatinine ratio: monthly 5
• Serum albumin: monthly 5

After achieving remission:

• Laboratory monitoring: every 3 months 5
• CD19+ B-cell counts: every 3-6 months (though B-cell depletion alone does not predict efficacy) 5, 7

Response Assessment Timeline

• Do not expect immediate proteinuria reduction—rituximab typically requires 3-6 months to show clinical benefit 1
• Assess clinical response at 3 months by measuring proteinuria and serum albumin 1
• Complete remission is defined as urine protein <0.3 g/day or protein-to-creatinine ratio <300 mg/g 1
• Most patients achieve remission within 3.26 months on average 3

Adjunctive Glucocorticoid Management

Critical timing consideration: Glucocorticoids should be continued for at least 2 weeks after the first rituximab infusion, then gradually tapered to avoid early relapse 1

Steroid Tapering Strategy

• Continue prednisone at current dose for 2 weeks post-rituximab 1
• Begin slow taper only after confirming initial response (decreasing proteinuria, rising albumin) 1
• Target complete steroid withdrawal by 3-6 months if remission is achieved 6, 3
• In one study, 70.4% of patients successfully discontinued all corticosteroids and immunosuppressants within 3 months after rituximab 6

Supportive Care Requirements

Infection Prophylaxis

Pneumocystis jirovecii prophylaxis is mandatory:

• Trimethoprim-sulfamethoxazole 800/160 mg three times weekly OR 400/80 mg daily 1, 8
• Continue for entire duration of rituximab therapy and for 6 months after last dose 8
• Alternative agents (atovaquone, dapsone) for sulfa-allergic patients 8

Thromboembolism Prevention

• Strongly consider prophylactic anticoagulation when serum albumin <20-25 g/L due to high thromboembolism risk in nephrotic syndrome 1
• Risk-stratify based on albumin level, proteinuria severity, and additional risk factors 1

Blood Pressure and Proteinuria Management

• ACE inhibitor or ARB should be used for proteinuria control, targeting blood pressure <130/80 mmHg 1
• Important caveat: Do not start ACE inhibitors/ARBs in patients presenting with abrupt-onset nephrotic syndrome, as these can cause acute kidney injury especially in MCD 5
• Wait until proteinuria begins responding to immunosuppression before initiating RAS blockade 5

Edema Management

• Loop diuretics as needed for symptomatic edema 5
• Sodium restriction to <2 g/day 5
• Monitor for volume depletion and hold diuretics during intercurrent illness 5

Monitoring for Adverse Events

Common Adverse Events (Monitor Closely)

• Infusion reactions (most common during first infusion): fever, chills, rigors, hypotension 4
• Cytopenias: neutropenia, thrombocytopenia, anemia 4
• Infections: upper respiratory infections, urinary tract infections 4
• Hypogammaglobulinemia: check IgG levels every 6 months; consider IVIG replacement if IgG <3 g/L with recurrent infections 8, 4

Serious Adverse Events (Rare but Critical)

• Progressive multifocal leukoencephalopathy (PML): Consider in any patient with new neurological symptoms; requires brain MRI and lumbar puncture 4
• Hepatitis B reactivation: Can be fatal; monitor HBV DNA in carriers 4
• Severe infusion reactions: anaphylaxis, cytokine release syndrome 4
• Cardiac arrhythmias: ventricular fibrillation, myocardial infarction (especially in patients with pre-existing cardiac disease) 4

Predictors of Response and Relapse

Favorable Prognostic Factors

• Higher baseline serum albumin predicts better sustained remission 6
• Treatment-naïve patients may have higher complete remission rates (88.9%) compared to relapsed patients (73.3%), though this difference was not statistically significant in one study 9

Risk Factors for Relapse

• Low serum albumin before rituximab is an independent risk factor for relapse within 2 years 6
• High CD56+CD16+ natural killer cell count after rituximab predicts higher relapse risk 6
• Nonselective proteinuria may lead to urinary rituximab loss, reducing drug exposure 7

Management of Rituximab-Resistant Disease

Definition of Resistance

• Failure to achieve at least partial remission after 6 months of rituximab therapy with adequate B-cell depletion 5
• Persistent proteinuria despite documented B-cell depletion (CD19+ <1%) 10

Treatment Options for Resistant Cases

Important finding: Rituximab can induce remission even when circulating B cells are absent, suggesting CD20+ T cells may play a pathogenic role 10

• Repeat rituximab dosing (1-2 infusions of 1000 mg each, 2 weeks apart) may be effective even without detectable B cells 10
• Calcineurin inhibitors (tacrolimus or cyclosporine) can be added to rituximab for synergistic effect 5
• Obinutuzumab (a type II anti-CD20 antibody) has shown success in rituximab-resistant MCD, achieving 12-month sustained remission 11
• Consultation with expert center is recommended for truly refractory cases 5

Special Considerations

Pregnancy Planning

• Rituximab is contraindicated during pregnancy due to risk of fetal B-cell lymphocytopenia 4
• Women of childbearing potential must use effective contraception during treatment and for 12 months after last dose 4
• If pregnancy is planned, switch to pregnancy-compatible agents (azathioprine, calcineurin inhibitors) at least 12 months before conception 4

Biosimilar Equivalence

• Rituximab biosimilars (e.g., rituximab-pvvr/Ruxience) are equally effective and well-tolerated for treating steroid-dependent MCD 12
• Biosimilars can be used interchangeably with reference rituximab for cost savings 12

Common Pitfalls to Avoid

1. Do not rely solely on B-cell counts to judge efficacy—clinical response (proteinuria, albumin) is more important than peripheral B-cell depletion 5, 7

2. Do not stop glucocorticoids immediately after rituximab—maintain steroids for at least 2 weeks post-infusion to prevent early relapse 1

3. Do not start ACE inhibitors/ARBs in acute nephrotic syndrome—wait until immunosuppression begins working to avoid AKI 5

4. Do not define treatment failure prematurely—allow 3-6 months for rituximab to demonstrate efficacy 1

5. Do not forget PCP prophylaxis—continue trimethoprim-sulfamethoxazole for 6 months after last rituximab dose 8

6. Do not overlook hepatitis B screening—reactivation can be fatal and requires antiviral prophylaxis in carriers 4

7. Do not assume resistance based on persistent proteinuria alone—improving serum albumin despite ongoing proteinuria may indicate secondary FSGS rather than active MCD 13